![Markus Warmuth](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Markus Warmuth
Chief Executive Officer at
MONTE ROSA THERAPEUTICS, INC.
Net worth: 6 M $ as of 31/10/2026
Profile
Markus Warmuth is currently Chief Executive Officer & Director at Monte Rosa Therapeutics AG, President, Chief Executive Officer & Director at Monte Rosa Therapeutics, Inc., Independent Director at IMV, Inc., Director at Ventus Therapeutics, Inc. and Ventus Therapeutics U.S., Inc., and Venture Partner at Versant Venture Management LLC.
Former roles include President & Chief Executive Officer at H3 Biomedicine, Inc. from 2011 to 2018, Director at Relay Therapeutics, Inc. from 2018 to 2019, Director-Kinase Biology at Novartis Institutes for Biomedical Research, Inc., and Head-Oncology Pharmacology at Novartis Institute for Functional Genomics, Inc. Education includes a doctorate from Ludwig-Maximilians-Universität München.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 16/07/2026 | 585,038 ( 0.69% ) | 6 M $ | 31/10/2026 |
Markus Warmuth active positions
| Companies | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Chief Executive Officer | 01/01/2020 |
| IMV INC. | Director/Board Member | 06/11/2018 |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes cancer drugs that modulates protein degradation pathways | Chief Executive Officer | - |
Ventus Therapeutics, Inc.
 Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics | Director/Board Member | 07/12/2021 |
Ventus Therapeutics U.S., Inc.
 Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Wholesales drugs | Director/Board Member | 07/12/2021 |
Former positions of Markus Warmuth
| Companies | Position | End |
|---|---|---|
| RELAY THERAPEUTICS, INC. | Director/Board Member | 01/08/2019 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Chief Executive Officer | 01/05/2018 |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Private Equity Investor | - |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Education of Markus Warmuth
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
76
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
IMV, Inc.
 IMV, Inc. BiotechnologyHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of genomic drugs | Commercial Services |
Relay Therapeutics, Inc.
 Relay Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage precision medicine company, which focus on enhancing small molecule therapeutic discovery in targeted oncology | Health Technology |
Monte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes cancer drugs that modulates protein degradation pathways | Health Technology |
Ventus Therapeutics, Inc.
Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics | Health Technology |
Ventus Therapeutics U.S., Inc.
Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Wholesales drugs | Distribution Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
- Stock Market
- Insiders
- Markus Warmuth
